BioPact Revenue and Competitors

Biopact is a nanoscale biomaterials company developing the MGMR intracellular delivery vehicle. MGMR is a cellular-engineering tool for biomanufacturing and agricultural processes which value efficient delivery of RNAs, peptides and genetic materials. MGMR is a highly-efficient intracellular delivery vehicle, consisting of a stabile dispersion of hollow, nanoscale tubules approximately 1/10,000th the width of a human hair. The high aspect-ratio, nanoscale profile of MGMR allows it to readily penetrate cells without compromising membrane integrity or inducing cytotoxicity. Its high surface-to-volume ratio and tunable surface chemistry allow it to readily transport both small and large-molecular payloads into the cytoplasm, including growth factors, oligonucleotides, proteins and gene-editing complexes. Biopact has evaluated the cytotoxicity profile of MGMR across multiple cell-lines and investigated safety and efficacy in murine biodistribution and clearance models. Our in vivo studies demonstrate that MGMR is biologically-inert, well-tolerated and rapidly cleared from non-targeted tissues. In a murine therapeutic model, MGMR loaded with doxorubicin (Dox) demonstrated a remarkable capability to rapidly concentrate drug in targeted tissues and extend half-life of its molecular cargo. Promising assessments of intracellular delivery performance in different eukaryotic cell-types suggest the potential for developing MGMR as a biomolecular delivery vehicle for various expression platforms and cell-factories of interest to agricultural and industrial applications, including mammalian cell-lines, yeasts, bacteria and plants. Robust cellular uptake observed with MGMR offers the potential to deliver molecular payloads to difficult-to-penetrate cell-types or those acutely sensitive to detergents and other conventional methods for transmembrane delivery.